6976 Stock Overview
Acepodia, Inc. operates as a clinical stage biotechnology company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Acepodia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.90 |
| 52 Week High | NT$65.00 |
| 52 Week Low | NT$25.60 |
| Beta | 0 |
| 1 Month Change | -3.29% |
| 3 Month Change | -4.12% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6976 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.4% | -1.6% | -2.3% |
| 1Y | n/a | -22.6% | 27.2% |
Return vs Industry: Insufficient data to determine how 6976 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 6976 performed against the TW Market.
Price Volatility
| 6976 volatility | |
|---|---|
| 6976 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6976 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6976's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sonny Hsiao | www.acepodia.com |
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address gaps in cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies.
Acepodia, Inc. Fundamentals Summary
| 6976 fundamental statistics | |
|---|---|
| Market cap | NT$15.86b |
| Earnings (TTM) | -NT$817.32m |
| Revenue (TTM) | NT$16.59m |
955.8x
P/S Ratio-19.4x
P/E RatioIs 6976 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6976 income statement (TTM) | |
|---|---|
| Revenue | NT$16.59m |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$16.59m |
| Other Expenses | NT$833.91m |
| Earnings | -NT$817.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,925.69% |
| Debt/Equity Ratio | 0% |
How did 6976 perform over the long term?
See historical performance and comparison